Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.

Floer M, Götte M, Wild MK, Heidemann J, Gassar ES, Domschke W, Kiesel L, Luegering A, Kucharzik T

Forschungsartikel (Zeitschrift)

Zusammenfassung

Syndecan-1 (Sdc1) plays a major role in wound healing and modulates inflammatory responses. Sdc1 expression is reduced in lesions of patients with ulcerative colitis. The aim of this study was to investigate the role of Sdc1 in murine dextran sodium sulfate (DSS)-induced colitis. DSS colitis was induced in Sdc1-deficient (knockout (KO)) and wild-type mice by oral administration of 3% DSS. KO mice exhibited a significantly increased lethality as compared with wild-type controls (61 versus 5%, P < 0.05). Impaired mucosal healing and prolonged recruitment of inflammatory cells in KO mice were accompanied by significant up-regulation of tumor necrosis factor-alpha, CC chemokine ligand 3/macrophage inflammatory protein-1alpha, and vascular cell adhesion molecule-1, as determined by histological correlation between 0 and 15 days after colitis induction, TaqMan low-density array analysis, and quantitative real-time PCR. Treatment from days 7 through 14 with enoxaparin, a functional analogue of the Sdc1 heparan sulfate chains, significantly reduced lethality of KO mice due to DSS-induced colitis, which was correlated with improved mucosal healing. In vitro, Sdc1-deficient polymorphonuclear cells displayed increased adhesion to endothelial cells and intercellular adhesion molecule-1, and enoxaparin reverted adhesion to wild-type levels. Small interfering RNA-mediated knockdown of Sdc1 expression resulted in reduced basic fibroblast growth factor-mediated mitogen-activated protein kinase signaling and reduced Caco-2 cell proliferation. We conclude that Sdc1 has a protective effect during experimental colitis. The modification of missing Sdc1 function by heparin analogues may emerge as a promising anti-inflammatory approach.

Details zur Publikation

FachzeitschriftAmerican Journal of Pathology
Jahrgang / Bandnr. / Volume176
Ausgabe / Heftnr. / Issue1
Seitenbereich146-157
StatusVeröffentlicht
Veröffentlichungsjahr2010
Sprache, in der die Publikation verfasst istEnglisch
DOI10.2353/ajpath.2010.080639
StichwörterHumans; Wound Healing; Enoxaparin; Mice; Caco-2 Cells; Animals; Neutrophils; MAP Kinase Signaling System; Intercellular Adhesion Molecule-1. Dextran Sulfate; Cell Adhesion; Gene Expression Regulation; Inflammation; Syndecan-1. Intestines; Lymphoid Tissue; Fibroblast Growth Factor 2. Cell Proliferation; RNA Small Interfering; Gene Knockdown Techniques; Colitis; Humans; Wound Healing; Enoxaparin; Mice; Caco-2 Cells; Animals; Neutrophils; MAP Kinase Signaling System; Intercellular Adhesion Molecule-1. Dextran Sulfate; Cell Adhesion; Gene Expression Regulation; Inflammation; Syndecan-1. Intestines; Lymphoid Tissue; Fibroblast Growth Factor 2. Cell Proliferation; RNA Small Interfering; Gene Knockdown Techniques; Colitis

Autor*innen der Universität Münster

Floer, Werner Martin
Medizinische Klinik B (Med B)
Götte, Martin
Klinik für Frauenheilkunde und Geburtshilfe
Heidemann, Jan
Medizinische Klinik B (Med B)
Kiesel, Ludwig
Klinik für Frauenheilkunde und Geburtshilfe

Projekte, aus denen die Publikation entstanden ist

Laufzeit: 01.01.2010 - 31.12.2012
Gefördert durch: Deutsch-Israelische Stiftung für Wissenschaftliche Forschung und Entwicklung
Art des Projekts: Gefördertes Einzelprojekt
Laufzeit: 01.01.2010 - 31.12.2010 | 1. Förderperiode
Gefördert durch: DFG - Internationale Kooperationsanbahnung
Art des Projekts: Gefördertes Einzelprojekt

Promotionen, aus denen die Publikation resultiert

Role of the heparan sulfate sulfotransferase HS3ST2 in breast cancer cell motility and invasiveness
Promovend*in: Gassar, Ezeddin Salem | Betreuer*innen: Götte, Martin; Stock, Christian; Kiesel, Ludwig
Zeitraum: bis 01.04.2011
Promotionsverfahren erfolgt(e) an: Promotionsverfahren an der Universität Münster

Habilitationen, aus denen die Publikation resultiert

Rolle des Heparansulfatproteoglykans Syndecan-1 als Modulator von Entzündungsvorgängen und Tumorprogression
Habilitand*in: Götte, Martin | Gutachter*innen: Kiesel, Ludwig
Zeitraum: 01.01.2008 - 12.04.2011
Habilitationsverfahren erfolgt(e) an: Habilitationsverfahren erfolgt(e) an der Universität Münster